Advertising review board upholds ruling against Tru Niagen's "clinically proven" claims
The upheld ruling against Tru Niagen shows advertising reviewers judge "clinically proven" supplement claims by what consumers understand, not by how the company classifies the claim.
A National Advertising Review Board (NARB) panel has upheld a National Advertising Division (NAD) ruling that Niagen Bioscience must stop using "clinically proven" and certain health-benefit claims for its Tru Niagen dietary supplement [1][2]. The appellate decision, reported in May 2026, also rejected the company's argument that a claim's status as a structure/function statement under federal law lowers the evidence needed to support it [2].
NAD recommended on March 16, 2026, that Niagen modify or discontinue the claims, after a challenge from Reus Research LLC, a competitor that also sells a supplement intended to raise NAD+ levels in the body [1].
At the center of the case was the claim that Tru Niagen is "clinically proven to significantly increase NAD+ levels, and help maintain them with daily use," plus a claim that NAD+ levels rise within hours and show significant increases within two weeks of use [1]. The record included studies showing that nicotinamide riboside (NR), the active ingredient in Tru Niagen, can raise NAD+ levels under certain conditions [1]. NAD concluded that differences in study design, populations, duration, endpoints and conditions of use limited how far that evidence supported the broad claim, and recommended both the "clinically proven" claim and the timing claim be dropped [1].
NAD also reviewed organ-level claims such as "supports heart health" and "supports brain health," vitality and anti-aging claims, and cellular-level statements such as "supports cellular energy that your heart cells need" [1]. It said cellular-level claims can, depending on context, convey functional health benefits to consumers, and it drew a line between evidence of biomarker or mechanistic changes and evidence of functional outcomes in people [1]. Where the record did not substantiate functional benefits, including cardiovascular, cognitive, immune, metabolic and anti-aging outcomes, NAD recommended the claims be discontinued or modified [1]. It recommended discontinuing certain consumer testimonials and said influencer posts must disclose material connections clearly in both the audio and visual portions of the content, consistent with the Federal Trade Commission's Endorsement Guides [1]. Niagen agreed during the proceeding to permanently discontinue claims about reproductive health, sleep improvement and "Made in the USA," which NAD did not review on the merits [1].
On appeal, Niagen argued that NAD weighed individual studies in isolation instead of the totality of the evidence, and that it recategorized qualified cellular and structure/function statements as broader implied claims [2]. "Niagen Bioscience is deeply disappointed by the NARB panel's decision, which we believe applies an overly restrictive standard that is inconsistent with long-standing dietary supplement law, scientific practice and established advertising precedent," said Carlos Lopez, Niagen's senior vice president and general counsel [2]. The NARB panel concluded that NAD "applied the proper legal standard" and followed FTC precedent, and that the criteria for advertising claims are separate from FDA oversight of structure/function claims [2]. "NARB's decision confirms that the message conveyed to consumers is what matters, not the advertiser's regulatory framing," said Roman Miroedov, product development lead at Cata-Kor, the brand that brought the challenge [2].
Compliance consultant Asa Waldstein told SupplySide Supplement Journal that a double-blind, placebo-controlled human trial is often the gold standard for a "clinically proven" claim, and that "the real question is whether the evidence is competent, reliable and closely matched to what consumers are likely to take away" [2].
Why it matters for patients
People taking or considering GLP-1 medications may see supplements marketed alongside those treatments. Neither the NAD recommendation nor the NARB decision names a GLP-1 drug or a GLP-1 supplement, and how this reasoning would apply to any specific product has not been reported [1][2]. What the case does show is how a national advertising review body currently reads a phrase like "clinically proven" on a supplement: the test is the message the ad conveys to consumers, not how the advertiser classifies the claim internally [2]. Waldstein's summary is that a claim has to stay tightly aligned with the evidence, and the evidence has to match the product form, dose and use pattern a consumer would actually follow [2].
Two other parts of the ruling affect what patients see. Testimonials that convey unsupported improvements in health, vitality or function were recommended for discontinuance, and paid influencer content must disclose the connection in the audio as well as in on-screen text [1].
What happens next
Niagen said in its advertiser statement that it "will appeal NAD's decision" after the March 16 ruling [1], and after the panel decision said it was deeply disappointed and described the standard as unworkable [2]. Whether the company plans further action has not been reported. For compliance purposes, NAD treats the claims Niagen voluntarily dropped, reproductive health, sleep improvement and "Made in the USA," as though NAD had recommended their discontinuance and the company agreed to comply [1]. No deadlines tied to GLP-1 supplements have been disclosed.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.